Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.4M
4M shares
52-week range
$0.79 – $6.25
0% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
24.40%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124.4K | $165.5K | $164.5K | $87.8K | $88.6K | $9.0K | $11.0K | $6.0K |
| Cost of revenue | $70.4K | $45.5K | $50.6K | $47.9K | $28.5K | $3.6K | $4.4K | $2.2K |
| Gross profit | $54.0K | $120.0K | $113.9K | $39.8K | $60.1K | $5.4K | $6.6K | $3.8K |
| Gross margin | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% |
| R&D | $96.6K | $0 | $0 | $109.2K | $6.3M | $2.0M | $2.4M | $2.3M |
| Operating income | −$1.1M | −$1.1M | −$1.1M | −$3.1M | −$10.2M | −$5.6M | −$5.7M | −$6.1M |
| EBITDA | −$1.1M | −$6.6M | −$35.0M | $23.6M | −$10.1M | −$5.2M | −$5.4M | −$6.0M |
| Net income | −$13.7M | −$8.5M | −$36.3M | $19.2M | −$10.1M | −$5.3M | −$5.5M | −$6.0M |
| Net margin | -10977.2% | -5126.1% | -22082.2% | 21892.8% | -11449.3% | -58739.7% | -49940.7% | -99916.8% |
| EPS (diluted) | -11351.33 | -5017.67 | -626.88 | 56.10 | -9.28 | -3.76 | -3.71 | -2.52 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23M | $-1.57 | $-1.57–$-1.57 | 1 |
| 2027 | $34M | $-1.51 | $-1.51–$-1.51 | 1 |
| 2028 | $60M | $-1.46 | $-1.46–$-1.46 | 1 |
| 2029 | $94M | $5.74 | $5.74–$5.74 | 1 |
Forward consensus · source: Financial Modeling Prep
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
www.creativemedicaltechnology.comNo one on the platform currently holds CELZ.
No tracked institution reports a position in CELZ as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-06-12 | 1-for-10reverse |
| 2021-11-10 | 1-for-500reverse |
| 2020-02-03 | 1-for-150reverse |
No one on the platform has traded CELZ yet.
| $4M |
| — |
| APREAprea Therapeutics, Inc. | $0.82 | +3.67% | $5M | — |
| BCDABioCardia, Inc. | $1.21 | +0.83% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CELZ Could you tell me what might be causing this drop? Thanks to anyone who can answer.
View on StockTwits ↗$CELZ about 1.6 million shares to go......so maybe Wednesday it recovers a little.....but doubtful
View on StockTwits ↗$CELZ if this company knew what they were doing, they would hire traders to run up their stock 200%+ and then diliute, not how they are doing it now. other nano cap biotech stocks usually do this to dilute
View on StockTwits ↗$CELZ maybe they will do a penis fixer medicine update to spike the share price.....lol
View on StockTwits ↗$CELZ they need to suspend the remaining offering and wait for better market conditions.
View on StockTwits ↗$CELZ its going to need a lower price to sell the 2 million shares remaining......should be fun....lol
View on StockTwits ↗$CELZ The MULN of biotech. Can't maintain listing price?...just do another reverse split! Who cares about shareholders?
View on StockTwits ↗$CELZ 3 more days of pain.....still 2.3 million shares to go
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 81.3× sales vs its 522.8× historical median P/S.
Fair value ≈ $5.21 · price $0.81 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.